PubMed
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
Attie KM, Borgstein NG, Yang Y, et al. Muscle Nerve. 2013
Compare
ACE-031 vs Humanin
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
ACE-031
308 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 62% · Mixed 22% · Unfavorable overall 16%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Joint comfort
-149
Recovery
-31
Digestive comfort
-151
Skin appearance
-99
Appetite control
-47
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site reaction
-53
Anxiety
-132
Flushing
-6
Headache
-103
GI discomfort
-48
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 100–200 mcg
Reports span 25–1000 mcg
25–50
4
50–100
14
100–200
18
200–400
9
400–600
6
600–1000
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
timing32stacking10side effects28ace-03116
How repeat users are trending
Among repeat reporters, 57% said they felt similar to their last entry, 30% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 68 repeat reporters
Humanin
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
6
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
1–2 mg
2
2+ mg
4
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Sources (8)
Published sources linked on the ACE-031 and Humanin wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
Campbell C, McMillan HJ, Mah JK, et al. Muscle Nerve. 2017
- Wiki study page →Source
PubMed
Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
Baig MH, Ahmad K, Moon JS, et al. Front Physiol. 2022
- Wiki study page →Source
ClinicalTrials.gov
ACE-031 (ActRIIB-Fc) studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Humanin: a novel mitochondrial-derived peptide that protects against cellular stress
Hashimoto Y, Niikura T, Ito Y, et al. Proc Natl Acad Sci USA. 2003
- Wiki study page →Source
PubMed
Humanin and the mitochondria in Alzheimer disease
Mitchell AC, Jiang S, Peterhoff CM, et al. Mol Neurodegener. 2015
- Wiki study page →Source
PubMed
Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases
Hazafa A, Batool A, Ahmad S, et al. Life sciences. 2021
- Wiki study page →Source
PubMed
Role of humanin, a mitochondrial-derived peptide, in cardiovascular disorders
Rochette L, Meloux A, Zeller M, et al. Archives of cardiovascular diseases. 2020